collection
https://read.qxmd.com/read/35966881/precision-medicine-based-on-the-phenotypic-differences-in-peripheral-t-helper-cells-in-patients-with-psoriatic-arthritis-one-year-follow-up-outcomes
#1
JOURNAL ARTICLE
Ippei Miyagawa, Shingo Nakayamada, Masanobu Ueno, Yusuke Miyazaki, Naoaki Ohkubo, Yoshino Inoue, Satoshi Kubo, Yoshiya Tanaka
Purpose: We validated the one-year effectiveness of strategic treatment with biological disease-modifying anti-rheumatic drugs (bDMARDs) based on peripheral T-lymphocytic phenotyping and explored the impact of treatment on T helper lymphocytic phenotypes. Methods: Ninety-seven patients were registered in this study. One-year treatment response was compared between the two groups: the strategic bDMARDs treatment group ( n = 41), in which bDMARDs were selected based on peripheral blood lymphocyte analysis, and the standard bDMARDs treatment group ( n = 56), in which the patients underwent no strategic selection of bDMARDs and phenotyping...
2022: Frontiers in Medicine
https://read.qxmd.com/read/30191421/efficacy-of-certolizumab-pegol-with-and-without-concomitant-use-of-disease-modifying-anti-rheumatic-drugs-over-4-years-in-psoriatic-arthritis-patients-results-from-the-rapid-psa-randomized-controlled-trial
#2
RANDOMIZED CONTROLLED TRIAL
J A Walsh, A B Gottlieb, B Hoepken, T Nurminen, P J Mease
To report long-term efficacy of certolizumab pegol (CZP) treatment with and without concomitant DMARDs in patients with psoriatic arthritis (PsA). RAPID-PsA (NCT01087788) was double-blind and placebo-controlled to week 24, dose-blind to week 48, and open-label to week 216. Patients had active PsA with ≥ 1 failed DMARD. At baseline, patients were randomized 1:1:1 to CZP 200 mg every 2 weeks: CZP 400 mg every 4 weeks: placebo. CZP-randomized patients continued their dose into open-label. Observed case efficacy data are reported to week 216 for week 0 CZP-randomized patients (dose combined) with and without baseline DMARD use (DMARD+/DMARD-)...
December 2018: Clinical Rheumatology
https://read.qxmd.com/read/33479721/improvement-from-ixekizumab-treatment-in-patients-with-psoriatic-arthritis-who-have-had-an-inadequate-response-to-one-or-two-tnf-inhibitors
#3
RANDOMIZED CONTROLLED TRIAL
Bruce Kirkham, Carlos Sesin, Amanda M Gellett, Aubrey T Sprabery, Chen-Yen Lin, Anthony Turkiewicz
OBJECTIVE: To evaluate the efficacy of ixekizumab (IXE), a monoclonal antibody selectively targeting interleukin-17A, in patients with inadequate response to one or two TNF inhibitors (TNFi). METHODS: A phase 3 study (SPIRIT-P2; NCT02349295) randomized patients with PsA with inadequate response or intolerance to one or two TNFi to receive 80-mg IXE every 2 weeks (n = 123) or every 4 weeks (n = 122) after a 160-mg starting dose or placebo (PBO; n = 118) through week 24...
September 1, 2021: Rheumatology
https://read.qxmd.com/read/33106286/brodalumab-in-psoriatic-arthritis-results-from-the-randomised-phase-iii-amvision-1-and-amvision-2-trials
#4
RANDOMIZED CONTROLLED TRIAL
Philip J Mease, Philip S Helliwell, Kasper Fjellhaugen Hjuler, Kyle Raymond, Iain McInnes
OBJECTIVE: To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA). METHODS: Adult patients with active PsA and inadequate response to, or intolerance to, conventional treatment were enrolled into two phase III studies (NCT02029495 and NCT02024646) and randomised 1:1:1 to receive subcutaneous brodalumab 140 mg or 210 mg or placebo at weeks 0, 1 and every 2 weeks up to 24 weeks...
February 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/32434812/eular-recommendations-for-the-management-of-psoriatic-arthritis-with-pharmacological-therapies-2019-update
#5
JOURNAL ARTICLE
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu, Peter V Balint, Heidi Bertheussen, Wolf-Henning Boehncke, Gerd R Burmester, Juan D Canete, Nemanja S Damjanov, Tue Wenzel Kragstrup, Tore K Kvien, Robert B M Landewé, Rik Jozef Urbain Lories, Helena Marzo-Ortega, Denis Poddubnyy, Santiago Andres Rodrigues Manica, Georg Schett, Douglas J Veale, Filip E Van den Bosch, Désirée van der Heijde, Josef S Smolen
OBJECTIVE: To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA). METHODS: According to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined. RESULTS: The updated recommendations comprise 6 overarching principles and 12 recommendations...
June 2020: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/31349876/disease-interception-with-interleukin-17-inhibition-in-high-risk-psoriasis-patients-with-subclinical-joint-inflammation-data-from-the-prospective-ivepsa-study
#6
RANDOMIZED CONTROLLED TRIAL
Eleni Kampylafka, David Simon, Isabelle d'Oliveira, Christina Linz, Veronika Lerchen, Matthias Englbrecht, Juergen Rech, Arnd Kleyer, Michael Sticherling, Georg Schett, Axel J Hueber
BACKGROUND: A specific subset of psoriasis patients is characterized by subclinical inflammatory changes. These patients frequently present with arthralgia and have a higher risk to develop psoriatic arthritis (PsA). We hypothesized that IL-17A inhibition in this subset of patients can intercept the link between skin and joint disease and resolves pain and inflammatory changes. METHODS: Psoriasis, but no PsA, patients were included in the open prospective exploratory Interception in very early PsA (IVEPSA) study...
July 26, 2019: Arthritis Research & Therapy
https://read.qxmd.com/read/29893222/efficacy-and-safety-of-guselkumab-in-patients-with-active-psoriatic-arthritis-a-randomised-double-blind-placebo-controlled-phase-2-study
#7
RANDOMIZED CONTROLLED TRIAL
Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, Yanli Zhuang, William Barchuk, Xie L Xu, Elizabeth C Hsia
BACKGROUND: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. METHODS: We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 rheumatology and dermatology practices in Canada, Germany, Poland, Romania, Russia, Spain, and the USA...
June 2, 2018: Lancet
https://read.qxmd.com/read/29573849/dactylitis-a-hallmark-of-psoriatic-arthritis
#8
REVIEW
Gurjit S Kaeley, Lihi Eder, Sibel Z Aydin, Marwin Gutierrez, Catherine Bakewell
OBJECTIVE: Dactylitis-long considered a hallmark clinical feature of psoriatic arthritis (PsA)-occurs in 16-49% of patients with PsA. In this review, we discuss the pathology of dactylitis in PsA and clinical and imaging tools used to diagnose and monitor dactylitis. METHODS: PubMed literature searches were conducted using the terms psoriatic arthritis, dactylitis, pathology, imaging, ultrasound, magnetic resonance imaging, clinical, and indices. Articles were deemed relevant if they provided insight into the pathology, diagnosis, and/or monitoring of dactylitis in PsA, or if they discussed clinical or imaging indices used to assess dactylitis...
October 2018: Seminars in Arthritis and Rheumatism
https://read.qxmd.com/read/30656673/methotrexate-for-psoriatic-arthritis
#9
JOURNAL ARTICLE
Tom D Wilsdon, Samuel L Whittle, Tilenka Rj Thynne, Arduino A Mangoni
BACKGROUND: Psoriatic arthritis is an inflammatory disease associated with joint damage, impaired function, pain, and reduced quality of life. Methotrexate is a disease-modifying anti-rheumatic drug (DMARD) commonly prescribed to alleviate symptoms, attenuate disease activity, and prevent progression of disease. OBJECTIVES: To assess the benefits and harms of methotrexate for psoriatic arthritis in adults. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, the WHO International Clinical Trials Registry Platform, and www...
January 18, 2019: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/30635024/weight-loss-improves-disease-activity-in-patients-with-psoriatic-arthritis-and-obesity-an-interventional-study
#10
JOURNAL ARTICLE
Eva Klingberg, Annelie Bilberg, Sofia Björkman, Martin Hedberg, Lennart Jacobsson, Helena Forsblad-d'Elia, Hans Carlsten, Björn Eliasson, Ingrid Larsson
BACKGROUND: Obesity is over-represented in patients with psoriatic arthritis (PsA) and associated with higher disease activity, poorer effect of treatment and increased cardiovascular morbidity. Studies on the effects of weight loss are however needed. This study aimed to prospectively study the effects of weight loss treatment with very low energy diet (VLED) on disease activity in patients with PsA (CASPAR criteria) and obesity (body mass index BMI ≥ 33 kg/m2 )...
January 11, 2019: Arthritis Research & Therapy
https://read.qxmd.com/read/30499246/special-article-2018-american-college-of-rheumatology-national-psoriasis-foundation-guideline-for-the-treatment-of-psoriatic-arthritis
#11
JOURNAL ARTICLE
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny, Jennifer Kwan-Morley, Janice Lin, Paula Marchetta, Philip J Mease, Joseph F Merola, Julie Miner, Christopher T Ritchlin, Bernadette Siaton, Benjamin J Smith, Abby S Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C Coates, Alice Gottlieb, Marina Magrey, W Benjamin Nowell, Ana-Maria Orbai, Soumya M Reddy, Jose U Scher, Evan Siegel, Michael Siegel, Jessica A Walsh, Amy S Turner, James Reston
OBJECTIVE: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). METHODS: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA...
January 2019: Arthritis & Rheumatology
https://read.qxmd.com/read/29618121/precision-medicine-using-different-biological-dmards-based-on-characteristic-phenotypes-of-peripheral-t-helper-cells-in-psoriatic-arthritis
#12
JOURNAL ARTICLE
Ippei Miyagawa, Shingo Nakayamada, Kazuhisa Nakano, Satoshi Kubo, Shigeru Iwata, Yusuke Miyazaki, Maiko Yoshikawa, Hiroko Yoshinari, Yoshiya Tanaka
Objectives: We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA. Methods: Of 64 patients with PsA resistant to MTX, 26 underwent bDMARDs therapy selected according to phenotypic differences in peripheral helper T cells on 8-colour flow cytometry. The efficacies of this strategic treatment and the standard treatment administered to the other 38 patients were evaluated at 6 months...
February 1, 2019: Rheumatology
https://read.qxmd.com/read/28572461/the-effects-of-5-year-etanercept-therapy-on-cardiovascular-risk-factors-in-patients-with-psoriatic-arthritis
#13
JOURNAL ARTICLE
Rabia Agca, Maaike Heslinga, Eva L Kneepkens, Carlo van Dongen, Michael T Nurmohamed
OBJECTIVE: To investigate the effects of etanercept (ETN) on lipid metabolism and other known cardiovascular disease (CVD) risk factors in patients with psoriatic arthritis (PsA). METHODS: In an observational cohort of 118 consecutive patients with PsA, CVD risk factors were assessed over 5 years. Mixed-model analyses were performed to investigate the effects of ETN therapy on CVD risk factors over time. RESULTS: Disease Activity Score in 28 joints, C-reactive protein (CRP), and erythrocyte sedimentation rate decreased during therapy with ETN...
September 2017: Journal of Rheumatology
https://read.qxmd.com/read/26669925/minimal-disease-activity-and-remission-in-psoriatic-arthritis-patients-treated-with-anti-tnf-%C3%AE-drugs
#14
JOURNAL ARTICLE
Fabio Massimo Perrotta, Antonio Marchesoni, Ennio Lubrano
OBJECTIVE: A state of remission is the target of therapy in chronic arthritis. The aim of the present study was to assess the rate of minimal disease activity (MDA) and remission in patients with psoriatic arthritis (PsA) treated with tumor necrosis factor (TNF-α) blockers. Disease characteristics and predictors of MDA were also evaluated. METHODS: Patients fulfilling the ClASsification for Psoriatic ARthritis (CASPAR) criteria and treated with TNF-α blockers adalimumab, etanercept, or golimumab were enrolled and prospectively followed every 4 months for 1 year in a clinical practice setting...
February 2016: Journal of Rheumatology
https://read.qxmd.com/read/26660203/pharmacological-treatment-of-psoriatic-arthritis-a-systematic-literature-review-for-the-2015-update-of-the-eular-recommendations-for-the-management-of-psoriatic-arthritis
#15
REVIEW
Sofia Ramiro, Josef S Smolen, Robert Landewé, Désirée van der Heijde, Maxime Dougados, Paul Emery, Maarten de Wit, Maurizio Cutolo, Susan Oliver, Laure Gossec
OBJECTIVE: To update the evidence on the efficacy and safety of pharmacological agents in psoriatic arthritis (PsA). METHODS: Systematic literature review of randomised controlled trials comparing pharmacological interventions in PsA: non-steroidal anti-inflammatory drugs, glucocorticoid, synthetic disease modifying antirheumatic drugs (sDMARDs) either conventional or targeted, biologicals (bDMARDs), placebo or any combination. Main outcomes were American College of Rheumatology (ACR)20-50, Psoriasis Area Severity Index 75, radiographic progression, and withdrawals due to adverse events (AEs)...
March 2016: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/26644232/european-league-against-rheumatism-eular-recommendations-for-the-management-of-psoriatic-arthritis-with-pharmacological-therapies-2015-update
#16
JOURNAL ARTICLE
L Gossec, J S Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, R Landewé, S Oliver, D Aletaha, N Betteridge, J Braun, G Burmester, J D Cañete, N Damjanov, O FitzGerald, E Haglund, P Helliwell, T K Kvien, R Lories, T Luger, M Maccarone, H Marzo-Ortega, D McGonagle, I B McInnes, I Olivieri, K Pavelka, G Schett, J Sieper, F van den Bosch, D J Veale, J Wollenhaupt, A Zink, D van der Heijde
BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members...
March 2016: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/26509055/what-makes-psoriatic-and-rheumatoid-arthritis-so-different
#17
REVIEW
Douglas James Veale, Ursula Fearon
In many ways, it may be easier to highlight what rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have in common. They are both common conditions characterised by a spectrum of features or clinical manifestations in different organ systems that have led many to conclude that they are actually 'disease syndromes'. Furthermore, many of the organ systems that are affected in both conditions are the same: skin, joints, eyes, vasculature and even the immune system. Indeed, some clinicians fail to recognise these two common arthritides as distinct...
2015: RMD Open
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.